Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIGILANT depemokimab in type 2 inflammatory COPD
NL-OMON61037Phase 3Recruiting
- Sponsor
- GSK
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of depemokimab in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Annualized rate of moderate/severe exacerbations. Started Sep 2026; status: recruiting.
02
Drugs
depemokimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON61037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61037.